Sophia Hammer-Hansen

Sophia Hammer-Hansen

Auto-generated profile, based on publicly available information

Sophia Hammer-Hansen

Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
PDF file
MEMarie Bayer Elming
Marie Bayer Elming
SHSophia Hammer-Hansen
Sophia Hammer-Hansen
IVInga Voges
Inga Voges
ENEvangelia Nyktari
Evangelia Nyktari
ARAnna Axelsson Raja
Anna Axelsson Raja
JTJens Jakob Thune
Jens Jakob Thune
Background: Patients with nonischemic systolic heart failure are at an increased risk of sudden cardiac death, but more discriminating tools are needed to identify those patients likely to benefit from implantable cardioverter-defibrillator (ICD) implantation. Whether right ventricular (RV) ejection fraction (RVEF) can identify patients with nonischemic systolic heart failure more likely to benefit from ICD implantation is not yet known. Methods: In this post hoc analysis of the DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients with Nonischemic Systolic Heart Failure on Mortality), patients with nonischemic systolic heart failure randomized to ICD or control underwent cardiovascular magnetic resonance. RV systolic dysfunction was defined as RVEF ≤45%. Cox regression assessed the effects of RV function and ICD implantation on all-cause mortality, sudden cardiac death, and cardiovascular death. Results: Overall, 239 patients had interpretable images of RV volume. Median RVEF was 51%, RV systolic dysfunction was present in 75 (31%) patients, and 55 (23%) patients died. RVEF was an independent predictor of all-cause mortality, hazards ratio 1.34 per 10% absolute decrease in RVEF (95% CI, 1.05–1.70), P =0.02. There was a statistically significant interaction between RVEF and the effect of ICD implantation ( P =0.001). ICD implantation significantly reduced all-cause mortality in patients with RV systolic dysfunction, hazards ratio 0.41 (95% CI, 0.17–0.97), P =0.04 but not in patients without RV systolic dysfunction, hazards ratio 1.87 (95% CI, 0.85–3.92), P =0.12, ( P =0.01 for the difference in effect of ICD between RV groups). Conclusions: In this post hoc analysis of the DANISH trial, ICD therapy was associated with survival benefit in patients with biventricular heart failure. These findings need confirmation in a prospective study. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00542945.

1 August 2011 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AGAnders M. Greve
Anders M. Greve
EGEva Gerdts
Eva Gerdts
KBKurt Boman
Kurt Boman
CGChrista Gohlke-Baerwolf
Christa Gohlke-Baerwolf
ARAnne B. Rossebø
Anne B. Rossebø
KWKristian Wachtell
Kristian Wachtell

12 December 2024 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
CSCosima M. Schmid
Cosima M. Schmid
AGAnne Gregor
Anne Gregor
ARAnna Ruiz
Anna Ruiz
CBCarmen Manso Bazús
Carmen Manso Bazús
IHIsabella Herman
Isabella Herman
CZChristiane Zweier
Christiane Zweier
While mostly de novo truncating variants in SCAF4 were recently identified in 18 individuals with variable neurodevelopmental phenotypes, knowledge on the molecular and clinical spectrum is still limited. We assembled data on 50 novel individuals with SCAF4 variants ascertained via GeneMatcher and personal communication. With detailed evaluation of clinical data, in silico predictions and structural modeling, we further characterized the molecular and clinical spectrum of the autosomal dominant SCAF4-associated neurodevelopmental disorder. The molecular spectrum comprises 25 truncating, eight splice-site and five missense variants. While all other truncating variants were classified as pathogenic/likely pathogenic, significance of one C-terminal truncating variant, one splice-site variant and the missense variants remained unclear. Three missense variants in the CTD-interacting domain of SCAF4 were predicted to destabilize the domain. Twenty-three variants occurred de novo, and variants were inherited in 13 cases. Frequent clinical findings were mild developmental delay with speech impairment, seizures, and skeletal abnormalities such as clubfoot, scoliosis or hip dysplasia. Cognitive abilities ranged from normal IQ to severe intellectual disability (ID), with borderline to mild ID in the majority of individuals. Our study confirms the role of SCAF4 variants in neurodevelopmental disorders and further delineates the associated clinical phenotype.

3 November 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
MBMaria Bejerholm Boelman
Maria Bejerholm Boelman
THThomas Hansen
Thomas Hansen
MSMatthias Nybro Smith
Matthias Nybro Smith
SHSophia Hammer‐Hansen
Sophia Hammer‐Hansen
ACAlex Hørby Christensen
Alex Hørby Christensen
BDBirgitte Rode Diness
Birgitte Rode Diness
Pathogenic variants in several genes involved in the function or regulation of smooth muscle cells (SMC) are known to predispose to congenital heart disease and thoracic aortic aneurysm and dissection (TAAD). Variants in MYLK are primarily known to predispose to TAAD, but a growing body of evidence points toward MYLK also playing an essential role in the regulation of SMC contraction outside the aorta. In this case report, we present a patient with co‐occurrence of persistent ductus arteriosus (PDA) and thoracic aortic dissection. Genetic analyses revealed a novel splice acceptor variant (c.3986‐1G > A) in MYLK, which segregated with disease in the family. RNA‐analyses on fibroblasts showed that the variant induced skipping of exon 24, which resulted in an in‐frame deletion of 101 amino acids. These findings suggest that MYLK‐associated disease could include a broader phenotypic spectrum than isolated TAAD, including PDA and obstructive pulmonary disease. Genetic analyses could be considered in families with TAAD and PDA or obstructive pulmonary disease.

13 May 2024 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
SHSophia Hammer-Hansen
Sophia Hammer-Hansen
USUlrik Stoltze
Ulrik Stoltze
EBEmil Bartels
Emil Bartels
THThomas van Overeem Hansen
Thomas van Overeem Hansen
ABAnna Byrjalsen
Anna Byrjalsen
BDBirgitte Rode Diness
Birgitte Rode Diness
The care for patients with serious conditions is increasingly guided by genomic medicine, and genomic medicine may equally transform care for healthy individual if genomic population screening is implemented. This study examines the medical impact of opportunistic genomic screening (OGS) in a cohort of patients undergoing comprehensive genomic germline DNA testing for childhood cancer, including the impact on their relatives. Medical actionability and uptake after cascade testing in the period following disclosure of OGS results was quantified. A secondary finding was reported to 19/595 (3.2%) probands primarily in genes related to cardiovascular and lipid disorders. After a mean follow up time of 1.6 years (Interquartile range (IQR): 0.57-1.92 yrs.) only 12 (63%) of these variants were found to be medically actionable. Clinical follow up or treatment was planned in 16 relatives, and as in the probands, the prescribed treatment was primarily betablockers or cholesterol lowering therapy. No invasive procedures or implantation of medical devices were performed in probands or relatives, and no reproductive counseling was requested. After an average of 1.6 years of follow-up 2.25 relatives per family with an actionable finding had been tested. This real-world experience of OGS grants new insight into the practical implementation effects and derived health care demands of genotype-first screening. The resulting health care effect and impact on demand for genetic counseling and workup in relatives extends beyond the effect in the probands.

13 November 2023 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
DLDorte L. Lildballe
Dorte L. Lildballe
AFAnja Lisbeth Frederiksen
Anja Lisbeth Frederiksen
BSBitten Schönewolf-Greulich
Bitten Schönewolf-Greulich
CBCharlotte Brasch-Andersen
Charlotte Brasch-Andersen
CLCharlotte Kvist Lautrup
Charlotte Kvist Lautrup
BDBirgitte R. Diness
Birgitte R. Diness